Densitas® Selects CancerIQ to Power Lifetime Risk, Patient Adherence as Part of its Industry Leading Mammography Quality AI Platform
Densitas Inc, an artificial intelligence and technology company, announced on Sunday that it has partnered with the cancer prevention service CancerIQ to include Cancer IQ’s Tyrer-Cuzick Version 8 risk calculator in its breast cancer screening offerings. This 8th version, released in March of 2018, uses further-improved patient and historical data to predict the likelihood of future breast cancer diagnoses.
Founder and CEO of Densitas Inc. Mo Abdolell expressed his excitement with the announcement in the press release, stating, “Our collaboration with CancerIQ reflects our commitment to furnishing care providers with best-in-class solutions for breast health.” He went on to say, “We are delighted to count CancerIQ with their industry-leading expertise… among our elite circle of premier industry partners, supporting the provision of peerless mammography quality and ultimately saving more lives.”
Founded in 2011, Densitas Inc. has worked hard to establish itself as a provider of robust breast cancer screening, advanced medical analytics, sophisticated trend-detection, and more using artificial intelligence in the medical technology industry. As stated on the Densitas website, “Our solutions present clinical care teams with on-demand actionable information and digitized workflows to systematically improve mammography quality, organizational and workflow efficiencies, and evidence based decision making.”
CancerIQ’s addition to the list of Densitas’ industry partners shows the continued dedication towards being at the forefront of breast cancer imaging, prediction, and prevention that Densitas has made itself known for over the past decade. More information about the announcement can be found in the full article below.
Read the full press release here.
See related materials: